New mobile apps support education, safety, and adherence needs of seizure patients

625

Adherent Health has announced the introduction of patient support apps for two novel medications used in the treatment of seizures and epilepsy, Oxtellar XR (oxcarbazapine extended-release tablets) and Trokendi XR (topiramate extended-release capsules). 

Developed under the guidance of epilepsy, neurology, pharmacy, and specialty nurse advisors, these patient support apps, now available in the Mobile Health Library (MHL) system, have been designed to better address the education, safety, and adherence needs of physicians, nurses, and pharmacists in clinical practice. “MHL engages both clinicians and patients on their terms, which today for most people means simple, mobile, and private,” says Tracy A Glauser, director, Comprehensive Epilepsy Center, Cincinnati Children’s Hospital Medical Center, “Having the important patient support resources available at your fingertips helps us better address the medication-specific needs of our patients, parents, and caregivers,” continues Glauser.

 


“Mobile app adoption rates are high across all medication-taking age groups, with many already using mobile apps on their smartphones or tablets,” says Todd Horich, executive director of Marketing, Supernus Pharmaceuticals. “Making our education and patient support services also available as apps in Mobile Health Library, helps us better support the treatment needs and communications preferences of clinicians, and of patients prescribed our medications,” continues Horich.

 


“By more simply integrating brand content and services that support safety, education, and medication adherence, MHL apps help address the patient understanding, safe-use, and outcomes attainment needs of physicians, nurses, pharmacists, patients, caregivers, and payers,” says Peter Pitts, chief regulatory officer, Adherent Health; chairman, MHL Standards and Practices Board; former FDA associate commissioner. 

(Visited 23 times, 1 visits today)